BR9712782A - Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf) - Google Patents
Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)Info
- Publication number
- BR9712782A BR9712782A BR9712782-5A BR9712782A BR9712782A BR 9712782 A BR9712782 A BR 9712782A BR 9712782 A BR9712782 A BR 9712782A BR 9712782 A BR9712782 A BR 9712782A
- Authority
- BR
- Brazil
- Prior art keywords
- pde
- tnf
- necrosis factor
- tumor necrosis
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção:<B>"DERIVADOS DE INDAZOL SUBSTITUìDO E SEU USO COMO INIBIDORES DE FOSFODIESTEROSE (PDE) E FATOR DE NECROSE DE TUMOR (TNF)"<D>. A invenção diz respeito a compostos da fórmula I e seus sais farmaceuticamente aceitáveis, em que R, R~ 1~ e R~ 2~ são conforme aqui definidos. A invenção diz ainda respeito a composições farmacêuticas que os contêm e a métodos de utilização dos compostos de fórmula I, ou seus sais aceitáveis, para inibição de fosfodiesterase (PDE) tipo IV ou da produção de fator de necrose de tumor (TNF) num mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2038596P | 1996-06-25 | 1996-06-25 | |
| PCT/IB1997/000630 WO1997049702A1 (en) | 1996-06-25 | 1997-06-02 | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9712782A true BR9712782A (pt) | 1999-12-07 |
Family
ID=21798354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9712782-5A BR9712782A (pt) | 1996-06-25 | 1997-06-02 | Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf) |
Country Status (43)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3102697A (en) | 1996-06-19 | 1998-01-07 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| IL128642A0 (en) * | 1996-09-04 | 2000-01-31 | Pfizer | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| US6248746B1 (en) | 1998-01-07 | 2001-06-19 | Euro-Celtique S.A. | 3-(arylalkyl) xanthines |
| EA200000385A1 (ru) * | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4) |
| BR9813926A (pt) * | 1997-11-04 | 2000-09-19 | Pfizer Prod Inc | Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos |
| US6362213B1 (en) | 1999-12-23 | 2002-03-26 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| WO2001047915A1 (en) * | 1999-12-23 | 2001-07-05 | Icos Corporation | Cyclic amp-specific phosphodiesterase inhibitors |
| US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
| US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| JP4535680B2 (ja) * | 2001-04-16 | 2010-09-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規１ｈ−インダゾール化合物 |
| DK1908463T3 (da) | 2001-12-14 | 2011-11-28 | Merck Serono Sa | Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator |
| WO2004009552A1 (en) | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
| RU2354648C2 (ru) * | 2002-07-19 | 2009-05-10 | Мемори Фармасьютиклз Корпорейшн | Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4 |
| EP1569908B1 (en) | 2002-11-19 | 2010-09-15 | Memory Pharmaceuticals Corporation | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
| US7226930B2 (en) * | 2003-04-18 | 2007-06-05 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors |
| US20090048255A1 (en) * | 2003-07-21 | 2009-02-19 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
| MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| CN101166733A (zh) | 2004-10-15 | 2008-04-23 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的吡唑衍生物 |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| WO2006129158A2 (en) * | 2005-05-30 | 2006-12-07 | Ranbaxy Laboratories Limited | 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1928866A1 (en) * | 2005-09-05 | 2008-06-11 | Ranbaxy Laboratories Limited | Substituted indazoles as inhibitors of phosphodiesterase type-iv |
| WO2007031838A1 (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN103497185A (zh) | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
| WO2010003084A2 (en) * | 2008-07-02 | 2010-01-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AU2010311511B2 (en) * | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| KR20220167804A (ko) * | 2021-06-11 | 2022-12-22 | 주식회사 메타센테라퓨틱스 | 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물 |
| KR20220167441A (ko) * | 2021-06-11 | 2022-12-21 | 주식회사 메타센테라퓨틱스 | 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB753573A (en) * | 1953-06-17 | 1956-07-25 | Ici Ltd | New dyestuffs intermediates |
| GB8707051D0 (en) * | 1986-04-15 | 1987-04-29 | Ici America Inc | Heterocyclic carboxamides |
| PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| TW223004B (pt) * | 1991-11-25 | 1994-05-01 | Sumitomo Chemical Co | |
| US5444038A (en) * | 1992-03-09 | 1995-08-22 | Zeneca Limited | Arylindazoles and their use as herbicides |
| AU677776B2 (en) * | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5554620A (en) * | 1993-09-14 | 1996-09-10 | Sterling Winthrop Inc. | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof |
| JPH07215952A (ja) * | 1993-12-06 | 1995-08-15 | Otsuka Pharmaceut Factory Inc | カテコール誘導体 |
| WO1996012720A1 (en) * | 1994-10-20 | 1996-05-02 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines and their use as medicaments |
-
1997
- 1997-06-02 AT AT97921992T patent/ATE244713T1/de not_active IP Right Cessation
- 1997-06-02 DK DK97921992T patent/DK0912558T3/da active
- 1997-06-02 PL PL97330974A patent/PL330974A1/xx unknown
- 1997-06-02 CN CN97195846A patent/CN1080260C/zh not_active Expired - Fee Related
- 1997-06-02 SK SK1765-98A patent/SK176598A3/sk unknown
- 1997-06-02 AU AU27857/97A patent/AU716376B2/en not_active Ceased
- 1997-06-02 CZ CZ984233A patent/CZ423398A3/cs unknown
- 1997-06-02 IL IL12703697A patent/IL127036A/en not_active IP Right Cessation
- 1997-06-02 WO PCT/IB1997/000630 patent/WO1997049702A1/en not_active Application Discontinuation
- 1997-06-02 EA EA199801047A patent/EA002274B1/ru not_active IP Right Cessation
- 1997-06-02 PT PT97921992T patent/PT912558E/pt unknown
- 1997-06-02 KR KR1019980710961A patent/KR20000022516A/ko active IP Right Grant
- 1997-06-02 JP JP50258998A patent/JP3152940B2/ja not_active Expired - Fee Related
- 1997-06-02 DE DE69723447T patent/DE69723447T2/de not_active Expired - Fee Related
- 1997-06-02 TR TR1998/02685T patent/TR199802685T2/xx unknown
- 1997-06-02 BR BR9712782-5A patent/BR9712782A/pt not_active Application Discontinuation
- 1997-06-02 SI SI9730553T patent/SI0912558T1/xx unknown
- 1997-06-02 ES ES97921992T patent/ES2201299T3/es not_active Expired - Lifetime
- 1997-06-02 CA CA002258285A patent/CA2258285C/en not_active Expired - Fee Related
- 1997-06-02 HU HU9903009A patent/HUP9903009A3/hu unknown
- 1997-06-02 EP EP97921992A patent/EP0912558B1/en not_active Expired - Lifetime
- 1997-06-05 HN HN1997000079A patent/HN1997000079A/es unknown
- 1997-06-05 US US08/869,358 patent/US6040329A/en not_active Expired - Fee Related
- 1997-06-10 PA PA19978432301A patent/PA8432301A1/es unknown
- 1997-06-12 GT GT199700075A patent/GT199700075A/es unknown
- 1997-06-19 AP APAP/P/1997/001020A patent/AP1025A/en active
- 1997-06-20 TW TW086108723A patent/TW434237B/zh not_active IP Right Cessation
- 1997-06-23 AR ARP970102755A patent/AR007456A1/es unknown
- 1997-06-23 MY MYPI97002820A patent/MY116915A/en unknown
- 1997-06-24 ZA ZA975581A patent/ZA975581B/xx unknown
- 1997-06-24 DZ DZ970104A patent/DZ2254A1/fr active
- 1997-06-24 TN TNTNSN97108A patent/TNSN97108A1/fr unknown
- 1997-06-24 ID IDP972170A patent/ID18579A/id unknown
- 1997-06-25 CO CO97035540A patent/CO4900056A1/es unknown
- 1997-06-25 MA MA24679A patent/MA24225A1/fr unknown
- 1997-06-25 HR HR970350A patent/HRP970350B1/xx not_active Application Discontinuation
-
1998
- 1998-11-27 IS IS4910A patent/IS4910A/is unknown
- 1998-12-11 OA OA9800235A patent/OA10934A/en unknown
- 1998-12-23 NZ NZ332752A patent/NZ332752A/en unknown
- 1998-12-23 NO NO986103A patent/NO986103D0/no not_active Application Discontinuation
- 1998-12-24 YU YU60198A patent/YU60198A/sh unknown
-
1999
- 1999-01-07 BG BG103056A patent/BG64052B1/bg unknown
- 1999-08-31 HK HK99103733A patent/HK1018700A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9712782A (pt) | Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf) | |
| NO991048L (no) | Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF) | |
| MY132499A (en) | Substituted indazole derivatives and related compounds | |
| EP1079826B1 (en) | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases | |
| HRP20070020T3 (en) | 1-(2h-pyrazol-3-yl)-3- 4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl -urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations | |
| BR9906013A (pt) | Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos | |
| FI951454A0 (fi) | 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä | |
| BRPI0410563A (pt) | derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase | |
| BRPI0518651A2 (pt) | composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes | |
| BRPI0313942B8 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
| BR0111548A (pt) | Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal | |
| NO331166B1 (no) | Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| BR0011274A (pt) | Derivados tipo indol como inibidores de p38 quinase | |
| BR0010746A (pt) | Derivados heterocìclicos úteis com agentes anticâncer | |
| DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
| DE69709493D1 (de) | Substituierte Indazolderivate | |
| BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
| BRPI9913542B8 (pt) | derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos | |
| ES2376277T3 (es) | Uso del �?cido cafeico y dervados como agentes anticancerosos. | |
| ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
| AU2002249103A1 (en) | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors | |
| KR20180061063A (ko) | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| ECSP972102A (es) | Derivados del indazol sustituidos y compuestos relacionados | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |